1. Female cancer survivors exposed to alkylating-agent chemotherapy have unique reproductive hormone profiles 
Lauren Johnson, M.D., M.S.C.E., Mary D. Sammel, Sc.D., Allison Schanne, B.A., Lara Lechtenberg, B.A., Maureen Prewitt, B.S.N., Clarisa Gracia, M.D., M.S.C.E. 
Fertility and Sterility 
Volume 106, Issue 7, Pages e2 (December 2016)
DOI: /j.fertnstert
Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

2. Figure 1
Daily adjusted urinary metabolites levels among cancer survivors, same-age control subjects, and late-reproductive-age control subjects. Data centered on the day of luteal transition (day 0) and presented by cycle day. (A) Urinary pregnanediol glucuronide (PDG). (B) Urinary estrone conjugate (E1c). (C) Urinary FSH. (D) Urinary LH.
Fertility and Sterility  , e2DOI: ( /j.fertnstert )
Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

3. Supplemental Figure 1
Daily adjusted urinary FSH levels among cancer survivors exposed to low-dose alkylating-agent chemotherapy, cancer survivors exposed to high-dose alkylating-agent chemotherapy, same-age control subjects, and late-reproductive-age control subjects. Data centered on the day of luteal transition (day 0) and presented by cycle day.
Fertility and Sterility  , e2DOI: ( /j.fertnstert )
Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions